A Gaussia Luciferase Reporter Assay for the Evaluation of Coronavirus Nsp5/3CLpro Activity

Overview

Journal Sci Rep

Specialty Science

Date 2024 Sep 5

PMID 39237598

Authors

Asimenia Vlachou

Rayhane Nchioua

Kerstin Regensburger

Frank Kirchhoff

Dorota Kmiec

Affiliations

Soon will be listed here.

Abstract

Human coronaviruses (hCoVs) infect millions of people every year. Among these, MERS, SARS-CoV-1, and SARS-CoV-2 caused significant morbidity and mortality and their emergence highlights the risk of possible future coronavirus outbreaks. Therefore, broadly-active anti-coronavirus drugs are needed. Pharmacological inhibition of the hCoV protease Nsp5 (3CLpro) is clinically beneficial as shown by the wide and effective use of Paxlovid (nirmatrelvir, ritonavir). However, further treatment options are required due to the risk of drug resistance. To facilitate the assessment of coronavirus protease function and its pharmacological inhibition, we developed an assay allowing rapid and reliable quantification of Nsp5 activity under biosafety level 1 conditions. It is based on an ACE2-Gal4 transcription factor fusion protein separated by a Nsp5 recognition site. Cleavage by Nsp5 releases the Gal4 transcription factor, which then induces the expression of Gaussia luciferase. Our assay is compatible with Nsp5 proteases from all hCoVs and allows simultaneous measurement of inhibitory and cytotoxic effects of the tested compounds. Proof-of-concept measurements confirmed that nirmatrelvir, GC376 and lopinavir inhibit SARS-CoV-2 Nsp5 function. Furthermore, the assay accurately predicted the impact of Nsp5 mutations on catalytic activity and inhibitor sensitivity. Overall, the reporter assay is suitable for evaluating viral protease activity.

References

Liu J, Ge C, Zha L, Lin L, Li R . Simple Nano-Luciferase-Based Assay for the Rapid and High-Throughput Detection of SARS-CoV-2 3C-Like Protease. Anal Chem. 2022; 95(2):714-719. DOI: 10.1021/acs.analchem.2c02590. View

Chen R, Gao Y, Liu H, Li H, Chen W, Ma J . Advances in research on 3C-like protease (3CL) inhibitors against SARS-CoV-2 since 2020. RSC Med Chem. 2023; 14(1):9-21. PMC: 9890616. DOI: 10.1039/d2md00344a. View

Kaizer A, Shapiro N, Wild J, Brown S, Cwik B, Hart K . Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. Int J Infect Dis. 2022; 128:223-229. PMC: 9792182. DOI: 10.1016/j.ijid.2022.12.028. View

Li P, Kim Y, Dampalla C, Nguyen H, Meyerholz D, Johnson D . Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment. mBio. 2023; 15(2):e0287823. PMC: 10865860. DOI: 10.1128/mbio.02878-23. View

Heilmann E, Costacurta F, Geley S, Mogadashi S, Volland A, Rupp B . A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Commun Biol. 2022; 5(1):391. PMC: 9046202. DOI: 10.1038/s42003-022-03277-0. View

Ip J, Chu A, Chan W, Leung R, Abdullah S, Sun Y . Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. EBioMedicine. 2023; 91:104559. PMC: 10101811. DOI: 10.1016/j.ebiom.2023.104559. View

Mahase E . Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021; 375:n2713. DOI: 10.1136/bmj.n2713. View

Corpet F . Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 1988; 16(22):10881-90. PMC: 338945. DOI: 10.1093/nar/16.22.10881. View

Kawashima S, Matsui Y, Adachi T, Morikawa Y, Inoue K, Takebayashi S . Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. Biochem Biophys Res Commun. 2023; 645:132-136. PMC: 9839456. DOI: 10.1016/j.bbrc.2023.01.040. View

10.

de Vries M, Mohamed A, Prescott R, Valero-Jimenez A, Desvignes L, OConnor R . A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL inhibitor PF-00835231 as a potential new treatment for COVID-19. J Virol. 2021; 95(7). PMC: 8139662. DOI: 10.1128/JVI.01819-20. View

11.

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

12.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

14.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

15.

Lora-Tamayo J, Maestro G, Lalueza A, Rubio-Rivas M, Villarreal Paul G, Fernandez F . Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study. J Infect. 2021; 82(6):276-316. PMC: 7877892. DOI: 10.1016/j.jinf.2021.02.011. View

16.

Tan H, Hu Y, Wang J . FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 M and PL. STAR Protoc. 2023; 4(2):102323. PMC: 10156985. DOI: 10.1016/j.xpro.2023.102323. View

17.

Ma C, Sacco M, Hurst B, Townsend J, Hu Y, Szeto T . Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020; 30(8):678-692. PMC: 7294525. DOI: 10.1038/s41422-020-0356-z. View

18.

Boras B, Jones R, Anson B, Arenson D, Aschenbrenner L, Bakowski M . Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat Commun. 2021; 12(1):6055. PMC: 8523698. DOI: 10.1038/s41467-021-26239-2. View

19.

Liu Y, Qin C, Rao Y, Ngo C, Feng J, Zhao J . SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response. mBio. 2021; 12(5):e0233521. PMC: 8546575. DOI: 10.1128/mBio.02335-21. View

20.

Reis G, Augusto Dos Santos Moreira Silva E, Carla Medeiros Silva D, Thabane L, Singh G, Park J . Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. JAMA Netw Open. 2021; 4(4):e216468. PMC: 8063069. DOI: 10.1001/jamanetworkopen.2021.6468. View